66. IgA nephropathy
199 clinical trials,   214 drugs   (DrugBank: 57 drugs),   32 drug target genes,   128 drug target pathways
Searched query = "IgA nephropathy", "IgA nephritis", "Berger disease", "IgA-IgG nephropathy"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT00396721 (ClinicalTrials.gov) | January 2006 | 3/11/2006 | Sirolimus Therapy for Poor Prognosis Immunoglobulin A Nephropathy | Pilot Trial of Treatment of Poor-Prognosis IgA Nephropathy With Low Exposure to Sirolimus. | Glomerulonephritis, IGA;Nephropathy, IGA;IGA Nephropathy | Drug: ACE inhibitor + statin;Drug: Sirolimus (study drug)+ACE inhibitor + statin | Josep m Cruzado | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | 18 Years | 70 Years | Both | 23 | Phase 2 | Spain |